Korea Takeda's "Susoctocog alfa," a bleeding treatment for patients with acquired haemophilia A, was designated as a rare drug by the MFDS on the 1st.

Hemophilia is a major hemorrhagic disease caused by a lack of clotting factors in the blood due to mutations in genes located on the X chromosome. Hemophilia A, caused by lack of coagulation factors, accounts for about 70% of all hemophilia patients.

Among them, acquired hemophilia A is an autoimmune antibody to coagulation factor VIII, which is a very rare condition in which coagulation factor VIII in the blood is suppressed and depleted, resulting in bleeding-related complications. It is reported that 0.2 to 1.48 out of 1 million people o